StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$7.00−0.07 (-0.99%)

Close on Nov 19, 2026Market cap $462.35MP/E –Yield –

Evolus free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Evolus's free cash flow for the twelve months ending Jun 30, 2026 was -$18.28M. For fiscal 2025 it was -$45.71M. The highest annual figure on record is -$13.22M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.71M–
FY2024Dec 31, 2024-$19.47M–
FY2023Dec 31, 2023-$34.48M–
FY2022Dec 31, 2022-$86.53M–
FY2021Dec 31, 2021-$33.78M–
FY2020Dec 31, 2020-$58.69M–
FY2019Dec 31, 2019-$93.73M–
FY2018Dec 31, 2018-$25.68M–
FY2017Dec 31, 2017-$13.22M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.64M–
Q1 FY2026Mar 31, 2026-$10.37M–
Q4 FY2025Dec 31, 2025$11.35M+159.7%
Q3 FY2025Sep 30, 2025-$15.62M–
Q2 FY2025Jun 30, 2025-$25.48M–
Q1 FY2025Mar 31, 2025-$15.95M–
Q4 FY2024Dec 31, 2024$4.37M+623.5%
Q3 FY2024Sep 30, 2024-$6.04M–
Q2 FY2024Jun 30, 2024-$6.94M–
Q1 FY2024Mar 31, 2024-$10.87M–
Q4 FY2023Dec 31, 2023$604.00K–
Q3 FY2023Sep 30, 2023-$953.00K–
Q2 FY2023Jun 30, 2023-$13.32M–
Q1 FY2023Mar 31, 2023-$20.81M–
Q4 FY2022Dec 31, 2022-$9.64M–
Q3 FY2022Sep 30, 2022-$17.56M–
Q2 FY2022Jun 30, 2022-$21.12M-231.0%
Q1 FY2022Mar 31, 2022-$38.21M–
Q4 FY2021Dec 31, 2021-$9.44M–
Q3 FY2021Sep 30, 2021-$32.13M–
Q2 FY2021Jun 30, 2021$16.12M–
Q1 FY2021Mar 31, 2021-$8.34M–
Q4 FY2020Dec 31, 2020-$2.28M–
Q3 FY2020Sep 30, 2020-$13.83M–
Q2 FY2020Jun 30, 2020-$14.06M–
Q1 FY2020Mar 31, 2020-$28.51M–
Q4 FY2019Dec 31, 2019-$15.92M–
Q3 FY2019Sep 30, 2019-$25.10M–
Q2 FY2019Jun 30, 2019-$33.50M–
Q1 FY2019Mar 31, 2019-$19.20M–
Q4 FY2018Dec 31, 2018-$12.01M–
Q3 FY2018Sep 30, 2018-$5.80M–
Q4 FY2017Dec 31, 2017-$1.00M–
Q3 FY2017Sep 30, 2017-$3.43M–

More Evolus figures

See a number that looks wrong?